A randomised prospective study to investigate the efficacy of corneal collagen cross linkage with riboflavin (vitamin B2) and ultraviolet A light (UVA) (370nm) to halt the progression of keratoconus

Submission date	Recruitment status No longer recruiting	Prospectively registered		
28/09/2007		☐ Protocol		
Registration date 28/09/2007	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
12/12/2013	Eye Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr David O'Brart

Contact details

Opthalmology F00, South Wing (Block 7) St. Thomas' Hospital Lambeth Palace Road London United Kingdom SE1 7RH +44 (0)207 1887 188 davidobrart@aol.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0013180304

Study information

Scientific Title

Study objectives

The aim is to determine whether the progression of keratoconus can be halted by strengthening the cornea by cross-linkage of its collagen using ultraviolet A (UVA) light and riboflavin (vitamin B) as a photosensitizer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomized, bilateral-controlled, prospective clinical investigation

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Keratoconus

Interventions

Randomized, bilateral-controlled, prospective clinical investigation (one eye acts as control while opposite acts as study) whereby riboflavin eye drops are applied and ultraviolet A light is shone into corneal surface. Study group undergoes full ophthalmic examination of both eyes, a full refraction test, corneal topography, keratometry, corneal pachymetry and applanation tonometry, at 1 day, week, month then month 3, 6, 12 & 18.

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

riboflavin (vitamin B2)

Primary outcome measure

To determine whether Riboflavin/ UVA corneal cross-linkage can prevent the progression of keratoconus. The non-treated eye will act as a control.

Secondary outcome measures

To determine whether Riboflavin/UVA corneal cross-linkage can reverse some of the bowing of the cornea caused by keratoconus. To determine whether non-treated eyes have progression of keratoconus compared to those eyes which underwent cross-linkage treatment.

Overall study start date

05/06/2006

Completion date

04/12/2007

Eligibility

Key inclusion criteria

36 patients with moderate bilateral keratoconus recruited from the corneal and contact lens clinics at Guy's and St. Thomas' NHS Foundation Trust. Inclusion criteria:

- 1. Age 18 to 70
- 2. Must fully understand the investigative nature of the study
- 3. Moderate to advanced bilateral keratoconus
- 4. No known allergies to pre- and post-operative medications Willingness to attend for follow-up examinations

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

36

Key exclusion criteria

- 1. Age below 18
- 2. Other pre-existing ophthalmic pathology
- 3. Previous ophthalmic surgery
- 4. Unilateral keratoconus
- 5. Severe keratoconus in which the cornea is so distorted that accurate refractive and corneal measurements cannot be obtained (in these eyes data confirming stability or progression is not possible)

Date of first enrolment

05/06/2006

Date of final enrolment

04/12/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Opthalmology

London United Kingdom SE1 7RH

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2007 Update - Department of Health

Sponsor details

The Department of Health, Richmond House, 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

Funder(s)

Funder type

Government

Funder Name

Guy's and St. Thomas' NHS Foundation Trust

Funder Name

Own account

Funder Name

NHS R&D Support Funding

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2011		Yes	No